AbCellera Biologics (ABCL) Total Non-Current Liabilities (2020 - 2026)

AbCellera Biologics (ABCL) has 7 years of Total Non-Current Liabilities data on file, last reported at $321.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 30.88% year-over-year to $321.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $321.7 million (up 30.88% YoY) and the FY2025 annual result came in at $325.7 million, up 42.96% from the prior year.
• Total Non-Current Liabilities slipped to $321.7 million in Q1 2026, from $325.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $328.0 million in Q2 2025 to a low of $159.8 million in Q2 2022.
• A 5-year average of $237.8 million and a median of $227.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 106.45% — and 2024, when it advanced 3.45%.
• Tracing ABCL's Total Non-Current Liabilities over 5 years: stood at $189.3 million in 2022, then increased by 14.5% to $216.8 million in 2023, then gained by 5.12% to $227.9 million in 2024, then jumped by 42.96% to $325.7 million in 2025, then slipped by 1.23% to $321.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $321.7 million (Q1 2026), $325.7 million (Q4 2025), and $323.2 million (Q3 2025), per Business Quant data.